Literature DB >> 12732998

Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenectomy in high-risk patients and elimination of surgeon-related factors: prospective, randomized, controlled trial.

Yan-Shen Shan1, Edgar D Sy, Pin-Wen Lin.   

Abstract

A prospective, randomized, controlled trial was performed to determine the efficacy of somatostatin in the prevention of pancreatic stump-related complications with elimination of surgeon-related factors in high-risk patients undergoing pancreaticoduodenectomy. From August 1997 to December 2000, 54 patients, 28 men and 26 women, with age ranged from 32 to 89 years, were randomly assigned to somatostatin group ( n = 27) or placebo group ( n = 27). Ninety-four percent of the patients had pancreatic and periampullary lesions; 6% had secondary lesion involving the duodenum such as local recurrent colon carcinoma and renal cell carcinoma. These patients received either standard pancreaticoduodenectomy or pylorus-preserving pancreaticoduodenectomy. An experienced surgeon performed all operations in same fashion to minimize the surgical factor. A transanastomotic tube was inserted into the pancreatic duct for diversion of pancreatic juice in the pancreaticojejunostomy for a 3-weeks period postoperatively. Intravenous infusion of somatostatin was given at a dose of 250 microg/hr in the somastotatin group and normal saline was given to the control group for 7 days postoperatively. There was one perioperative death in each group, resulting in a 3.7% mortality rate. In the somastotatin group, as compared to the placebo group, the incidence of overall morbidity and pancreatic stump related complications were significantly lower with a mean decrease of 50% pancreatic juice output and a slightly shorter duration of hospital stays. In conclusion, after excluding surgeon related factor, prophylactic use of somatostatin reduces the incidence and severity of pancreatic stump related complications in high-risk patients having pancreaticoduodenectomy via decreased secretion of pancreatic exocrine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732998     DOI: 10.1007/s00268-003-6693-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  34 in total

1.  THE RATIONALE OF RADICAL SURGERY FOR CANCER OF THE PANCREAS AND AMPULLARY REGION.

Authors:  A O Whipple
Journal:  Ann Surg       Date:  1941-10       Impact factor: 12.969

2.  Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects--a two-compartment open model.

Authors:  L T Ho; R L Chen; T Y Chou; J C Fong; P S Wang; C K Chou
Journal:  Clin Physiol Biochem       Date:  1986

3.  Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy.

Authors:  P W Lin; Y J Lin
Journal:  Br J Surg       Date:  1999-05       Impact factor: 6.939

4.  Surgical palliation for pancreatic cancer. The UCLA experience.

Authors:  S M Singh; W P Longmire; H A Reber
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

5.  The complications of pancreatectomy.

Authors:  M Trede; G Schwall
Journal:  Ann Surg       Date:  1988-01       Impact factor: 12.969

6.  Pancreatic and periampullary carcinoma. Experience with 200 patients over a 12 year period.

Authors:  R J Piorkowski; S W Blievernicht; W Lawrence; J Madariaga; J S Horsley; J P Neifeld; J J Terz
Journal:  Am J Surg       Date:  1982-02       Impact factor: 2.565

7.  Treatment of pancreatic cutaneous fistulas with a somatostatin analog.

Authors:  R A Prinz; J Pickleman; J P Hoffman
Journal:  Am J Surg       Date:  1988-01       Impact factor: 2.565

8.  An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy.

Authors:  C A Pellegrini; C F Heck; S Raper; L W Way
Journal:  Arch Surg       Date:  1989-07

9.  Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration.

Authors:  W Londong; M Angerer; K Kutz; R Landgraf; V Londong
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

10.  A simple, secure and universal pancreaticojejunostomy following pancreaticoduodenectomy.

Authors:  P W Lin; J C Lee; P C Lee; T W Chang; C J Hung; Y C Chang
Journal:  HPB Surg       Date:  1997
View more
  20 in total

Review 1.  A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma.

Authors:  Markus K Diener; Hanns-Peter Knaebel; Christina Heukaufer; Gerd Antes; Markus W Büchler; Christoph M Seiler
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

2.  Anastomotic leakage in pancreatic surgery.

Authors:  Stefano Crippa; Roberto Salvia; Massimo Falconi; Giovanni Butturini; Luca Landoni; Claudio Bassi
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 3.  Analysis of clinical trials evaluating complications after pancreaticoduodenectomy: a new era of pancreatic surgery.

Authors:  Manabu Kawai; Hiroki Yamaue
Journal:  Surg Today       Date:  2010-11-03       Impact factor: 2.549

Review 4.  Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma.

Authors:  Felix J Hüttner; Christina Fitzmaurice; Guido Schwarzer; Christoph M Seiler; Gerd Antes; Markus W Büchler; Markus K Diener
Journal:  Cochrane Database Syst Rev       Date:  2016-02-16

5.  Current surgical management of pancreatic cancer.

Authors:  Charles B Kim; Shuja Ahmed; Eddy C Hsueh
Journal:  J Gastrointest Oncol       Date:  2011-09

6.  Risk Factors and Management of Postoperative Pancreatic Fistula Following Pancreaticoduodenectomy: Single-center Experience.

Authors:  Zun-Xiang Ke; Jiong-Xin Xiong; Jin Hu; Heng-Yu Chen; Qin Li; Yi-Qing Li
Journal:  Curr Med Sci       Date:  2019-12-16

Review 7.  Clinical trials to reduce pancreatic fistula after pancreatic surgery-review of randomized controlled trials.

Authors:  Yuji Kitahata; Manabu Kawai; Hiroki Yamaue
Journal:  Transl Gastroenterol Hepatol       Date:  2016-03-16

8.  Pancreatic Fistula and Delayed Gastric Emptying After Pancreatectomy: Where do We Stand?

Authors:  Ammar A Javed; Kanza Aziz; Fabio Bagante; Christopher L Wolfgang
Journal:  Indian J Surg       Date:  2015-10-13       Impact factor: 0.656

9.  Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenectomy: increased delayed gastric emptying and reduced plasma motilin.

Authors:  Yan-Shen Shan; Edgar D Sy; Mei-Ling Tsai; Li-Ying Tang; P Shirley Li; Pin-Wen Lin
Journal:  World J Surg       Date:  2005-10       Impact factor: 3.352

Review 10.  Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma.

Authors:  Markus K Diener; Christina Fitzmaurice; Guido Schwarzer; Christoph M Seiler; Felix J Hüttner; Gerd Antes; Hanns-Peter Knaebel; Markus W Büchler
Journal:  Cochrane Database Syst Rev       Date:  2014-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.